Free Trial

Spectral Medical Q1 2024 Earnings Report

Spectral Medical logo
C$0.48 +0.01 (+1.06%)
(As of 12/20/2024 05:17 PM ET)

Spectral Medical EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Medical Revenue Results

Actual Revenue
$0.67 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Medical Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Spectral Medical Earnings Headlines

Spectral Medical Advances Amid Tigris Trial Challenges
The top TSX healthcare stocks under $1
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Spectral Medical Nears Completion of Tigris Trial
Spectral Medical Provides September Tigris Trial Update
See More Spectral Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Medical and other key companies, straight to your email.

About Spectral Medical

Spectral Medical (TSE:EDT) focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

View Spectral Medical Profile

More Earnings Resources from MarketBeat

Upcoming Earnings